Randomized study evaluating trifluridine/tipiracil (TAS-102) versus + trifluridine/tipiracil + bevacizumab as last-line therapy in patients with chemorefractory unresectable metastatic colorectal cancer (mCRC)
Pfeiffer, Per, Yilmaz, Mette, Möller, Sören, Maltha, Line, Krogh, Merete, Zitnjak, Daniela, Szameitat, Caroline Lemb, Hejlesen, Finn, Thomsen, Karina Gravgaard, Qvortrup, Camilla
Published in Journal of clinical oncology (01.02.2019)
Published in Journal of clinical oncology (01.02.2019)
Get full text
Journal Article